年内涨幅近26%，创新药ETF天弘(517380)昨日“吸金”1176万元，在创新药相关ETF中排名第一

Group 1 - The core viewpoint of the news highlights the performance and potential of the innovative drug sector, particularly focusing on the Tianhong Innovative Drug ETF (517380), which has seen a year-to-date increase of 25.96% as of June 4, 2023 [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] - The ETF has experienced a net inflow of 11.76 million yuan recently, indicating strong investor interest and confidence in the innovative drug sector [1] Group 2 - Recent developments in domestic innovative drugs were highlighted, particularly the presentation of self-developed anti-cancer drugs by China Biopharmaceutical at the American Society of Clinical Oncology (ASCO) annual meeting [2] - The "De Fu Combination" treatment showed promising results in clinical trials, outperforming the global leader in cancer treatment, Pembrolizumab, with a median progression-free survival of 11 months [2] - Analysts from Donghai Securities and Guosheng Securities express optimism about the innovative drug sector, emphasizing its solid underlying logic and potential for continued growth despite short-term market concerns [2]